|Other Names||Serine/threonine-protein kinase PINK1, mitochondrial, BRPK, PTEN-induced putative kinase protein 1, PINK1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6406b was selected from the PINK1 region of human PARK6 (PINK1). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Protects against mitochondrial dysfunction during cellular stress by phosphorylating mitochondrial proteins. Involved in the clearance of damaged mitochondria via selective autophagy (mitophagy) by mediating activation and translocation of PARK2. Targets PARK2 to dysfunctional depolarized mitochondria through the phosphorylation of MFN2. Activates PARK2 in 2 steps: (1) by mediating phosphorylation at 'Ser-65' of PARK2 and (2) mediating phosphorylation of ubiquitin, converting PARK2 to its fully-active form (PubMed:24660806, PubMed:24751536, PubMed:24784582, PubMed:25527291).|
|Cellular Location||Mitochondrion outer membrane; Single-pass membrane protein Cytoplasm, cytosol. Note=Localizes mostly in mitochondrion and the 2 proteolytic processed fragments of 55 kDa and 48 kDa localize mainly in cytosol|
|Tissue Location||Highly expressed in heart, skeletal muscle and testis, and at lower levels in brain, placenta, liver, kidney, pancreas, prostate, ovary and small intestine. Present in the embryonic testis from an early stage of development|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Defects in PINK1 are the cause of autosomal recessive early-onset Parkinson's disease 6 (PARK6). Six novel pathogenic PINK1 mutations suggest that PINK1 may be the second most common causative gene next to parkin in parkinsonism with the recessive mode of inheritance. Strong evidence indicates that, although important in mendelian forms of Parkinson's disease (PD), PINK1 does not influence the cause of sporadic nonmendelian forms of PD.
Rogaeva,E.,et al. Arch. Neurol. 61 (12), 1898-1904 (2004)Hatano,Y., et al. Ann. Neurol. 56 (3), 424-427 (2004)Healy,D.G., et al. Ann. Neurol. 56 (3), 329-335 (2004)Valente,E.M., et al. Science 304 (5674), 1158-1160 (2004)Nakajima,A., et al. Cancer Lett. 201 (2), 195-201 (2003)Unoki,M. and Nakamura,Y. Oncogene 20 (33), 4457-4465 (2001)
If you have any additional inquiries please email technical services at email@example.com.